CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 26 target
Drug / intervention
Simvastatin 40mg +1 moredrug
Likely dose
Simvastatin 40mgfrom record
Key inclusion· 4
  • Female patients with advanced (locally or distantly) triple-negative breast cancer confirmed by biopsy and immunohistochemistry
  • Planned to receive 8 cycles of AC-T chemotherapy
  • Age greater than 18 years
  • Willing to participate and sign informed consent
Key exclusion· 3
  • Pregnant or breastfeeding
  • Prior chemotherapy or current simvastatin therapy
  • Allergy to statins

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05550415
NCT05550415Phase 2RecruitingUpdate OverdueUpdated 20mo ago · Completion was 14mo ago
Enrollment Stalled
Long Recruiting
Update Overdue

Vimentin Expression-based Therapeutic Response in Triple Negative Breast Cancer Receiving Combination of Simvastatin and NAC: a Randomized, Double-Blind, Placebo-Controlled Trial

Indonesia University·interventional·Posted Sep 22, 2022·Updated Oct 3, 2024

In Brief

A Phase 2 clinical trial evaluating Simvastatin 40mg and Placebo for Triple Negative Breast Cancer and 2 related conditions. Currently recruiting, targeting 26 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

Introduction: Most cases of Triple Negative Breast Cancer (TNBC) have a high proliferation rate. TNBC is associated with a poor prognosis, a high recurrence rate, and a high incidence of distant metastases. The Epithelial-Mesenchymal Transition process (EMT) plays an essential role in the metastatic process. EMT markers were also more abundant in TNBC and contributed to a poorer TNBC prognosis. As an important EMT marker, the increased expression of vimentin also contributed to the increase in TNBC aggressiveness and resistance to chemotherapeutic agents. Through the mechanism of action in inhibiting the mevalonate pathway, statins can help inhibit the EMT process in metastases. Notably, simvastatin promotes the down-regulation of vimentin in breast cancer cells. The combination of statins and neoadjuvant chemotherapy (NAC) improves the cancer patient's response. This study is expected to evaluate the role of a combination between NAC and simvastatin on therapeutic response in TNBC patients through vimentin expression. Methods: This study is a double-blind, randomized, placebo-controlled trial conducted in Dr. Cipto Mangunkusumo National Central General Hospital. An expected total of 26 TNBC patients will be assessed for eligibility and asked for informed consent. Patients with the plan to have ACT (Doxorubicin hydrochloride, Cyclophosphamide, Paclitaxel) chemotherapy regimen will receive either a combination of ACT-Simvastatin (40 mg/day) or ACT-Placebo. The biopsy will be taken pre-NAC to make the histopathological diagnosis and examine the expression of vimentin. Patients will be evaluated for adverse effects reaction every cycle and the clinical response after 8 cycles. The post-intervention biopsy will be conducted after the cycle finish. The pathological response and vimentin expression will be reviewed from the obtained samples.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIndonesia
Collaborators--

Timeline

Phase 2RecruitingOverdue
2023202420252026
First PostedSep 22, 2022
Enrollment StartAug 19, 2022
Primary CompletionMay 1, 2025
Study CompletionAug 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 3.8 years ago

Interventions

Simvastatin 40mgdrug

The administration of Simvastatin 40 mg in addition to ACT regiment of neoadjuvant chemotherapy

Placebodrug

The administration of Placebo capsule 40 mg in addition to ACT regiment of neoadjuvant chemotherapy